Pfizer Inc
NYSE: PFE
$26.36
+$0.59 (+2.3%)
Closing Price on December 20, 2024
PFE Articles
For years, analysts and portfolio managers have anticipated the return of value stocks as the market has moved higher, and for years, they have continued to underperform growth stocks. However, that...
Published:
Fourth-quarter earnings kick off in a big way in 7 to 10 days, and earnings at some of the biggest and best U.S. companies are likely expected to decline for the third quarter running. Many top...
Published:
Analyst upgrades and downgrades to some major stocks were reported Thursday morning. Tech stocks set the tone in both directions.
Published:
The Johnson brothers started Johnson & Johnson in 1886 JHVEPhoto / iStock Editorial via Getty Images The iconic healthcare giant was started by Robert, James, and Edward Johnson in 1886 after...
Published:
After years of a low-interest rate environment, which has reversed in a big way over the last 18 months, many investors continue to turn to equities not only for growth potential but also for solid...
Published:
Pfizer Inc. (NYSE: PFE) was printing money during the Covid pandemic. Still, those days are way in the rearview mirror as investors not only see shrinking sales but also see the potential for a...
Published:
While many investment professionals suggest short Treasury paper and money markets, healthcare is the place in 2024 for long-term investors looking for growth and income. Demand is growing as the...
Published:
While many Wall Street firms are suggesting short Treasury paper and money markets now, for long-term investors looking for growth and income, healthcare is the place to be for the rest of 2023 and...
Published:
The stock market for the most part has had a solid year after a dreadful 2022, and those that owned any of the Magnificent 7 have had an incredible year. The reality is that the great majority of the...
Published:
For growth and income investors, it makes sense now to look at blue chip dividend stocks with big and dependable payouts. These six are well suited for what could be a difficult end to 2023 as the...
Published:
Pfizer stock has tumbled due to shrinking vaccine sales and the potential for a social and consumer backlash. Moderna stock has also been pounded.
Published:
Tuesday's top analyst upgrades and downgrades included Colgate-Palmolive, Crown Castle, Dollar General, D.R. Horton, Enphase Energy, Instacart, Netflix, Pfizer, Southern Company, UnitedHealth, Walt...
Published:
Private equity firms and institutions have been buying up top health care stocks like these seven for their strong total return potential and a degree of safety in what soon could be some very rough...
Published:
These five outstanding stocks come with big dividends and some big safety, making them ideal for worried investors looking to hedge or take the money and run to safe havens in what could be a rough...
Published:
After U.S. markets closed on Thursday, Ford beat estimates on both the top and bottom lines, posting a 12% year-over-year increase in revenue and a 5.9% increase in earnings per share (EPS). And even...
Published: